The Department of Health and Human Services on Saturday said the states with the greatest number of COVID-19 cases have been allotted doses of Gilead Sciences Inc.'s GILD-0.15% remdesivir based on their case counts. Some clinical groups last week had raised concerns about what hospitals and patients will have access to the drug, which is the first new medication to receive an authorization from the Food and Drug Administration as a COVID-19 therapy. Gilead has donated 1.5 million doses of the drug, which HHS is dispensing to states, which are then allocating to hospitals. Illinois (140 cases of remdesivir), New York (565 cases), New Jersey (110 cases), and Massachusetts (117 cases) have been allotted the most number of cases, each of which has 40 vials of remdesivir. The FDA [l:granted an emergency use authorization|https://www.marketwatch.com/story/how-gileads-remdesivir-became-the-leader-in-the-rush-to-find-a-treatment-for-covid-19-2020-05-01?mod=article_inline|NEW] to Gilead for remdesivir on May 1. Gilead's stock has gained 19.5% year-to-date, while the S&P 500 SPX+1.69% is down 9.3%.%.
ليست هناك تعليقات:
إرسال تعليق